openPR Logo
Press release

Global Cancer Immunotherapy Market Offers US$ 200 Billion Opportunity With 2300 Drug In Clinical Trials

07-18-2020 07:31 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Kuick Resarch

Global Cancer Immunotherapy Market Offers US$ 200 Billion

"Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026" Report Highlights:

• Global Cancer Immunotherapy Market Opportunity: > US$ 200 Billion
• Cancer Immunotherapy Clinical Trials: > 2300 Drugs In Trials
• Commercially Available Cancer Immunotherapies: > 120
• Cancer Vaccines Market Opportunity: > US$ 20 Billion
• Cancer Monoclonal Antibodies Market Opportunity: > US$ 90 Billion
• Marketed Cancer Monoclonal Antibodies': > 70 mAbs
• Sales, Market Opportunity, Dosage & Price Data: 300 Graphs/Charts
• Clinical Trials Insight By Phase, Company, Patient Segment, Drug Class

The research report “Global Cancer Immunotherapy Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” discusses the implications that the recent scientific research and development has brought in context to the ongoing trends and current market size of the cancer immunotherapy at global and regional level. Additionally, the report depicts the nature of the therapies and the structures that are followed by the cancer immunotherapy approach with detailed profiles of the pharmaceutical companies that are the keynote representer of immunotherapy products in the market.

Download Report:,-dosage,-price-and-clinical-trials-insight-2026.php

1. Immunotherapy for Cancer

1.1 Introduction to Cancer Immunotherapy
1.2 Advancement of Cancer Immunotherapy

2. Types of Cancer Immunotherapy

2.1 Specific Cancer Immunotherapy
2.1.1 Cancer Vaccines
2.1.2 Monoclonal Antibodies

2.2 Non-Specific Cancer Immunotherapy
2.2.1 Adoptive Cell Transfer Immunotherapy
2.2.2 Immune Checkpoint Inhibitors

3. Dynamics of Global Cancer Immunotherapy Landscape

3.1 Favorable Developmental & Commercialization Parameters
3.2 Issues to be Resolved in Expansion of Immunotherapy Horizon

4. Cancer Vaccines: Transforming The Immunotherapy Landscape

4.1 Prologue of Cancer Vaccines
4.2 Cancer Vaccines in Immunotherapy
4.3 Commercialization of Cancer Vaccines

5. Monoclonal Antibodies: New Era of Immunotherapy

5.1 Rudiments of Monoclonal Antibodies
5.2 Advents of Monoclonal Antibodies
5.3 Commercial Aspects of Monoclonal Antibodies

6. Trails of T-Cell Therapies

6.1 Adoptive Cell Transfer Technology
6.2 Strategies of Adoptive Cell Transfer
6.3 Commercial Aspects of Adoptive Cell Therapy

7. Application of Immune Checkpoint Inhibitors in Immunotherapy

7.1 Prelude to Immune Checkpoint Inhibitors
7.2 Implications of Immunecheck Point Inhibitors
7.3 Commercial Aspects of Immune Checkpoint Inhibitors

8. Role of Immunomodulators in Cancer Immunotherapy

8.1 Perspective of Immunomodulators
8.2 Clinical Aspects of Immunomodulators
8.3 Commercial Aspects of Immunomodulators

9. Development of Oncolytic Viral Immunotherapy

9.1 Concept to Oncolytic Viruses
9.2 Potential Approaches of Oncolytic Viruses
9.3 Commercial Aspects of Oncolytic Viruses

10. Cytokines & Cancer Immunotherapy

10.1 Fundamentals of Cytokines
10.2 Classification of Cytokines
10.3 Commercial Aspects of Cytokines

11. Interferons in Immunotherapy

11.1 Potentials of Interferons
11.2 Classification of Interferons
11.3 Clinical Applications of Interferons

12. Interleukins in Immunotherapy

12.1 Potentials of Interleukins
12.2 Clinical Applications of Interleukins

13. GM-CSF in Immunotherapy

13.1 Potentials of GM-CSF
13.2 Clinical Applications of GM-CSF

14. Market Aspects of Cancer Immunotherapy

14.1 Current Market Trends
14.2 Economic Aspects of Cancer Immunotherapy
14.3 Cancer Immunotherapy Cost by Product

15. Cancer Immunotherapy Pipeline Overview

15.1 By Drug Class
15.2 By Phase
15.3 By Company
15.4 By Target
15.5 By Patient Segment

16. Cancer Immune Check Point Inhibitors - Availability, Price, Dosage & Sales Analysis

16.1 Keytruda (Pembrolizumab)
16.2 Yervoy (Ipilimumab)
16.3 Opdivo (Nivolumab)
16.4 Tecentriq (Atizolizumab)
16.5 Bavencio (Avelumab)
16.6 Imfinzi (Darlumuvab)
16.7 Libtayo (Cemiplimab)

17. Cancer Monclonal Antibody Market - Availability, Price, Dosage & Sales Analysis

17.1 Herceptin (Trastuzumab)
17.2 Avastin (Bevacizumab)
17.3 MabThera/Rituxan (Rituximab)
17.4 Erbitux (Cetuximab)
17.5 Vectibix (Panitumab)
17.6 Arzerra (Ofatumumab)
17.7 Gazyva (Obinutuzumab)
17.8 Perjeta (Pertuzumab)

18. Bispecific Antibody Market - Availability, Price, Dosage & Sales Analysis

18.1 Blincyto (Blinatumomab)

19. Cancer Vaccine Market - Availability, Price, Dosage & Sales Analysis

19.1 Gardasil & Gardasil 9
19.2 Cervarix
19.3 Provenge (Sipuleucel – T)
19.4 Vaxira (Racotumomab)
19.5 CreaVax-RCC

20. Cancer Cytokines Drugs Market - Availability, Price, Dosage & Sales Analysis

20.1 Proleukin (Aldeslukin)
20.2 Intron A (Interferon Alpha-2b)
20.3 PegIntron (PegInterferon alpha-2b)
20.4 Sylatron (Peginterferon Alpha-2b)
20.5 Betaseron (Interferon Beta-1b)
20.6 Actimmune (Interferon Gamma-1b)
20.7 Ontak (Denileukin Diftitox)

21. Oncolytic Virus Market - Availability, Dosage, & Price Analysis

21.1 Imlygic
22. CAR-T Cell Therapy - Availability, Dosage, Price & Sales Analysis
22.1 Kymriah
22.2 Yescarta

23. Marketed Cancer Cell Therapies Drugs

23.1 T-Lymphocyte Cell Therapy(Immuncell-LC®)
23.2 Zalmoxis
23.4 Dendritic Cell-Activated Cytokine-Induced Killer Cells - Shanghai Jia Fu Medical

24. Marketed Cancer Cytokines Drugs

24.1 Aldesleukin (Proleukin®)
24.2 Denileukin Diftitox (ONTAK®)
24.3 Interferon Alpha (Multiferon®)
24.4 Interferon Alpha-2a (Roferon-A®)
24.5 Interferon Alpha-2a (Veldona®)
24.6 Interferon Alpha-2a Biosimilar(Inferon™/Inmutag™)
24.7 Interferon Alpha-2b(Intron® A)
24.8 Interferon Alpha-2b Biosimilar(Bioferon™)
24.9 Interferon Alpha-2b Biosimilar (Intalfa®)
24.10 Interferon Alpha-2b Biosimilar
24.11 Interferon Alpha-2b Biosimilar (ReliFeron®)
24.12 Interferon-Alpha-n3 (Alferon N®)
24.13 Interferon-Beta-1b (Feron®)
24.14 Interferon-Gamma (Ogamma®)
24.15 Interleukin-2 Biosimilar (Ilcass)
24.16 Teceleukin (Imunace™)

25. Marketed Cancer Vaccines

25.1 Bladder Cancer Vaccine (PACIS®)
25.2 Bladder Cancer Vaccine
25.3 BV NSCLC 001
25.4 Dendritic Cell Vaccine (CreaVax-HCC®, CreaVax-PC® & CreaVax-RCC®)
25.5 Human Papillomavirus Vaccine Quadrivalent (Gardasil®/Silgard®)
25.6 Human Papillomavirus Vaccine Recombinant Bivalent (Cervarix®)
25.7 Immuvac / Cadi 05
25.8 Immucyst / TheraCys
25.9 Melanoma Vaccine (MVax®)
25.10 Melanoma Vaccine (Melacine®)
25.11 Racotumomab (Vaxira®)
25.12 Reniale
25.13 Sipuleucel-T (Provenge®)
25.14 Tertomotide (LucaVax)
25.15 Vitespen (Oncophage®)

26. Marketed Cancer Monoclonal Antibodies

26.1 Bevacizumab
26.2 Trastuzumab Emtansine
26.3 Trastuzumab Subcutaneous
26.4 Brentuximab Vedotin
26.5 Catumaxomab
26.6 Ipilimumab
26.7 Nivolumab
26.8 Pembrolizumab
26.9 Pertuzumab
26.10 Rituximab
26.11 Trastuzumab
26.12 Gemtuzumab Ozogamicin
26.13 Others

27. Global Cancer Immunotherapy Market Future Prospects

28. Competitive Landscape

28.1 Abbvie
28.2 Advaxis
28.3 Altor BioScience
28.4 Amgen
28.5 Biogen Idec
28.6 Biogenomics
28.7 Celldex Therapeutics
28.8 Dendreon Corporation
28.9 Eli Lilly
28.10 Expression Genetics
28.11 Galena Biopharma
28.12 Genmab
28.13 Gilead Sciences
28.14 GlaxoSmithKline
28.15 ImmunoCellular Therapeutics
28.16 ImmunoGen
28.17 Inovio Pharmaceuticals
28.18 IRX Therapeutics
28.19 Merck
28.20 NeoStem Oncology
28.21 NewLink Genetics
28.22 Northwest Biotherapeutics
28.23 Novartis
28.24 Peregrine Pharmaceuticals
28.25 Pfizer
28.26 Philogen
28.27 Regulon
28.28 Roche
28.29 Seattle Genetics
28.30 ZymoGenetics

Neeraj Chawla


Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Immunotherapy Market Offers US$ 200 Billion Opportunity With 2300 Drug In Clinical Trials here

News-ID: 2092650 • Views: 462

More Releases from Kuick Resarch

Global CFTR Modulators Market Opportunity Clinical Trials Insight 2026
“Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” Report Highlights: • Global CFTR Modulators Market Opportunity: > US$ 20 Billion • Global CFTR Modulators Market Growth: 42% CAGR (2017 -2020) • Global CFTR Modulators Market Growth In 2020: 55% • Global CFTR Modulators Pipeline: 30 Drug • Commercially Available Bispecific Antibodies: 4 Drugs • Trikafta Market Share 2020: > 50% Download Report: “Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2026” provides
Gamma Delta T Cell Cancer Therapy Opportunity Clinical Trials Insight 2026
“Gamma Delta T Cell Cancer Therapy Opportunity & Clinical Trials Insight 2026” Report Highlights: • Commercialization Market Potential After Market Launch: > USD 4 Billion • Insight on Key Drugs In Research & Development • Global Gamma Delta T Cell Cancer Therapy Clinical Trials Insight • Gamma Delta T Cell Cancer Therapy In clinical Trials: > 15 Therapies • Gamma Delta T Cell Cancer Therapy Market Opportunity By Cancer Type • Adopted Approaches for Gamma Delta T Cell Therapy Download
Global Peptide Drug Conjugate Clinical Trial Report 2026
Global Peptide Drug Conjugate Market & Clinical Trials Insight 2026 Report Highlights: • First FDA Approved Peptide Drug Conjugate: Pepaxto (Melphalan Flufenamide) • Pepaxto Clinical & Commercial Insight: Dosage, Patent, Price, Sales Forecast • Peptide Drug Conjugate Sales Opportunity: US, Europe, Japan & South Korea • Global Peptide Drug Conjugate Clinical Pipeline: > 20 Drugs • Clinical Trials Insight by Company, Country, Indication • Patent Insight of Peptide Drug Conjugates • Profile & Clinical Pipeline Insight of Companies Developing Peptide Drug Conjugates Download Report: “Global Peptide
Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024
"Global Trispecific Antibodies Market Opportunity & Clinical Trials Insight 2024" Report Highlights: • Commutative Market Opportunity During Initial 5 years of Commercialization: > US$ 2 Billion • Trispecific Antibodies In Clinical Trials: > 8 Antibodies • Highest Phase of Development: Phase I/II • Cancer Dominating Trispecific Antibodies Trials: > 5 Antibodies • Numab Therapeutics Dominating the Trispecific Development Pipeline • Prevention & Second Line Therapy Key Focus of Development of Trispecific Antibodies Download Report: Trispecific cancer antibody therapy market at

All 5 Releases

More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk
Cancer Vaccines Market
Manufacturers in the cancer vaccines market are focusing on developing new vaccines in order to treat various cancers. Through this, they are expected to gain a competitive edge in the market and increase their market share. For instance, Gilead Science Inc., in 2017, acquired Kite Pharma Inc., which is involved in development of different type of immunotherapy and vaccines. Also, Treos Bio, in 2017, collaborated with Pharmaceutical Product Development, LLC
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top
Global Cancer Vaccines Market 2016: Liver cancer, Cervical cancer, Stomach cance …
Latest industry research report on Cancer vaccines are the type of immunotherapy (also named as biologic therapy), designed to boost body's natural defense against cancer. The body's natural immune system recognizes vaccine proteins as the foreign particles and sets up an immunity against them. According to World Health Organization (WHO), cancer is a leading cause of worldwide mortality registering ~14 million new cases and ~8.2 million cancer-related diseases in 2012. Personalized
Taking thyroid cancer seriously
With the increasing incidence rate of thyroid cancer in Metro Cebu, the Eduardo J. Aboitiz Cancer Center (EJACC) of the Ramon Aboitiz Foundation Inc. (RAFI) urged the public to undergo early screening and prevention measures to fight the disease. “Thyroid cancer is high on prognosis. It is preventable through various screening methods, such as physical examination and ultrasound of the neck, as well as some prevention measures, including regular exercise and